Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07863180
PHASE1/PHASE2

Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial

Sponsor: Prabesh Kanel

View on ClinicalTrials.gov

Summary

This research is studying a supplement called tributyrin in people with Progressive Supranuclear Palsy (PSP) to learn about its safety and tolerability as a potential treatment. The goal of this research study is to see if a similar supplementation regimen and virtual testing is feasible for people with PSP.

Official title: Tributyrin for PSP: Phase 1b Virtual Trial - Feasibility Study

Key Details

Gender

All

Age Range

45 Years - Any

Study Type

INTERVENTIONAL

Enrollment

15

Start Date

2026-09

Completion Date

2027-05

Last Updated

2026-10-07

Healthy Volunteers

No

Interventions

DRUG

Tributyrin

Post-biotic short chain fatty acid dietary supplement. Participants will take 500mg TID tributyrin supplement for 90 days +/- 7 days.

DRUG

Placebo

Participants will take 500mg TID placebo for 90 days +/- 7 days.

Locations (1)

Domino's Farms

Ann Arbor, Michigan, United States